What causes ataxia?

Ataxia results from damage to, or dysfunction of, the cerebellum or the sensory/motor pathways that feed into it. The main categories are:

• Genetic (hereditary) ataxias — spinocerebellar ataxias (SCA, over 40 genetic subtypes identified) and Friedreich’s ataxia, caused by inherited mutations that progressively damage cerebellar neurons, typically confirmed via genetic testing.
• Autoimmune and paraneoplastic ataxias — the immune system mistakenly targets cerebellar tissue, sometimes as a remote effect of an underlying cancer.
• Toxic and metabolic causes — chronic alcohol use, certain anti-seizure or chemotherapy medications, vitamin E or B12 deficiency, and some metabolic disorders.
• Vascular and structural causes — stroke, tumor, or degenerative lesions affecting the cerebellum or its connecting pathways.
• Multiple system atrophy (cerebellar type, MSA-C) — a progressive neurodegenerative condition combining ataxia with autonomic dysfunction.
• Sensory ataxia — caused by peripheral nerve or dorsal column damage rather than the cerebellum itself (e.g., severe diabetic neuropathy).

Why the cause matters for treatment planning

Current published research — including the Phase I/IIa human trial referenced under Scientific References — has focused specifically on spinocerebellar ataxias and, separately, multiple system atrophy (cerebellar type). Toxic or metabolic ataxias often improve substantially once the underlying cause (alcohol, medication, deficiency) is corrected — this should always be addressed first, independent of any regenerative therapy discussion. If your case involves suspected sensory ataxia from peripheral neuropathy rather than cerebellar dysfunction, our Neuropathy page and Diabetic Neuropathy page may be more directly relevant than this one.

What are the symptoms of ataxia?

Symptoms reflect loss of coordinated movement and typically develop gradually in hereditary forms, or suddenly in acquired forms like stroke:

• Unsteady, wide-based gait — often the earliest and most noticeable sign, with a tendency to stumble or need support.
• Poor limb coordination — clumsiness reaching for objects, overshooting or undershooting movements (dysmetria).
• Slurred, slow, or irregular speech (dysarthria) — a hallmark feature in many cerebellar ataxias.
• Abnormal eye movements — nystagmus (involuntary eye jerking) or difficulty tracking objects smoothly.
• Difficulty swallowing (dysphagia) — becomes more relevant as disease progresses and carries choking/aspiration risk.
• Tremor, particularly intention tremor that worsens as a hand approaches its target.

When to seek evaluation

Any new or worsening unsteadiness, falls, slurred speech, or swallowing difficulty warrants prompt neurological evaluation — not a stem cell consultation as a first step. Getting an accurate diagnosis (see Diagnosis) determines whether the cause is genetic, acquired, or reversible, which changes the entire management plan.

How is ataxia diagnosed?

A confirmed diagnosis — including subtype where possible — is required before any regenerative treatment is proposed at Viezec:

Reports from these tests, especially genetic confirmation and a recent MRI, can be uploaded for a free specialist review before you travel for consultation.

Note: A diagnosis of “ataxia” alone on a referral letter isn’t enough to determine candidacy — the specific subtype materially changes both the evidence base and the realistic goals of treatment, which is why genetic and imaging confirmation are requested wherever possible.

Stem Cell Treatment for Ataxia

How does it work?

Regenerative approaches for ataxia are being studied for their potential to support cerebellar neuron survival, reduce local neuroinflammation, and provide neurotrophic (growth-factor) support to remaining neural circuits — not to regenerate lost cerebellar tissue outright. Cells are typically sourced from bone marrow or umbilical cord tissue, processed under GMP-certified lab conditions, and delivered via intrathecal administration to reach the cerebrospinal fluid surrounding the brain and spinal cord.

Who is a candidate?

You may be considered a candidate if you have:

• A confirmed diagnosis of spinocerebellar ataxia (any genetically confirmed subtype) or Friedreich’s ataxia
• Early-to-moderate disease stage, with meaningful functional capacity remaining
• Acquired ataxia (e.g., post-stroke, cerebellar type MSA) with stable overall neurological status
• No response, or limited response, to conventional symptomatic management alone

You are not likely to be an immediate candidate if your ataxia is caused by an active reversible condition (untreated vitamin deficiency, ongoing toxin exposure, active autoimmune process) — these are addressed first, since correcting them may resolve symptoms without any regenerative approach.

What to expect: the treatment process

1. Neurological and genetic diagnostic confirmation — reviewing MRI, genetic testing, and clinical exam findings.
2. Cell sourcing and GMP processing — from bone marrow, adipose tissue, or screened donor cord tissue.
3. Administration — typically intrathecal, occasionally combined with targeted injection depending on presentation (see Delivery Methods).
4. Intensive rehabilitation — physiotherapy, occupational therapy, and gait/balance training begin immediately alongside and after cell administration; this isn’t optional supportive care, it’s part of the protocol.
5. Structured follow-up — coordination and balance assessments at defined intervals to track functional change (see Improvements).

Most patients require a 5–7 day in-country stay for evaluation, administration, and initial rehabilitation, with remote follow-up continuing for 6–12 months. See our Delivery Methods section for how the administration route is chosen, and our general Stem Cell Therapy Protocol page for how protocols are individualized across conditions.

Stem Cell Delivery Methods for Ataxia

The delivery route for ataxia is chosen based on your specific diagnosis, disease pattern, and safety profile — not applied uniformly to every patient:

• Intrathecal administration — cells are introduced into the cerebrospinal fluid via lumbar puncture, allowing distribution around the brain and spinal cord. This is the most studied route for spinocerebellar ataxia in the published literature (see the Phase I/IIa trial under Scientific References).
• Intra-arterial administration — used in some published protocols for multiple system atrophy (cerebellar type), delivering cells via catheter into arterial circulation supplying the brain.
• Targeted/localized injection — considered in select cases where focal delivery is clinically indicated, though this is less common for diffuse cerebellar degeneration than for focal injuries.

All procedures use image-guided placement where relevant, are performed in GMP-standard facilities, and are followed by structured neurological monitoring for adverse events and functional response. For a broader explanation of how delivery routes are selected across conditions generally, see our Stem Cell Delivery Methods page.

Improvements Seen After Stem Cell Treatment for Ataxia

Reported improvements center on functional coordination and balance measures, tracked through structured rehabilitation follow-up rather than self-report alone.

What patients and clinical follow-up report

• Improved balance — reduced fall risk and greater walking confidence, typically attributed to combined gait retraining and neurological response.
• Better coordination — improvement in hand-eye coordination and fine motor tasks (writing, buttoning, eating) via task-specific occupational therapy.
• Functional safety — supported by home adaptations and assistive devices that extend independence alongside any biological response to treatment.
• Speech clarity — some patients report modest improvement in articulation, tracked through speech and swallowing assessments.

How improvement is monitored, not just reported

What the evidence does not yet show

Most currently published data comes from small clinical series, a single completed Phase I/IIa trial, and animal models — not large randomized trials. An ongoing Phase II RCT (NCT06397274, see Scientific References) is specifically designed to test this more rigorously. Until that data is available, individual improvement should be discussed with your treating specialist based on your specific subtype and disease stage, not a general expectation.

Mechanism of Action: How Stem Cells May Support Neurological Stability in Ataxia

Regenerative approaches for ataxia are studied through several proposed mechanisms, distinct from directly replacing lost cerebellar neurons:

• Neuroprotection — supporting survival of remaining cerebellar neurons rather than regenerating those already lost.
• Inflammation modulation — reducing neuroinflammatory processes linked to progression in genetic ataxias.
• Neurotrophic (growth factor) support — paracrine signaling that may improve communication along surviving neural circuits.
• Reduction of oxidative stress — a proposed contributor to slowing degeneration, studied primarily in animal models of SCA to date.

These mechanisms are described in the mouse and cell-culture studies referenced under Scientific References — human confirmation of each specific mechanism remains an active research question, not a settled finding. Treatment is performed under strict clinical supervision at our GMP-certified facility, consistent with the standards outlined in our Quality Control page.

Our Promise

• No cure claims. Stem cell therapy for ataxia is offered as an investigational, supportive option — never marketed as a cure, and never presented with a guaranteed outcome.
• Diagnosis-first approach. No protocol is proposed without confirmed genetic testing (where applicable), MRI findings, and neurological examination.
• Named, credentialed oversight. Treatment plans are reviewed by a qualified neurologist and regenerative medicine specialist.
• Regulatory transparency. Protocols operate within India’s ICMR framework for investigational stem cell use; this is disclosed directly, not left implicit.
• GMP-certified facilities. Cell processing occurs in GMP-certified laboratories.
• Written, itemized estimates. No flat public pricing, but a clear written cost estimate is provided after neurological and genetic report review, before any commitment.
• Rehabilitation as standard, not optional. Physiotherapy, occupational therapy, and gait training are built into every protocol from day one.
• Honest evidence communication. Where evidence is still developing — as with most ataxia subtypes — we say so directly and point to the specific studies our approach draws on, rather than implying stronger proof than currently exists.

Treatment Results

Patients treated for various ataxia subtypes at Viezec report outcomes including improved coordination, reduced dysmetria in daily tasks, better gait stability, and improved fine motor function — tracked via SARA scoring and functional assessment rather than subjective report alone.

Follow-up typically spans 6–12 months, combining balance testing, coordination assessment, and rehabilitation progress. Improvement depends heavily on ataxia subtype, disease duration at the time of treatment, and baseline neurological status — a genetically confirmed early-stage SCA patient and a late-stage MSA-C patient should not expect comparable outcomes, and our specialist team will set expectations accordingly during consultation.

As with all conditions we treat, this remains a research-oriented, investigational approach. It is not a guaranteed cure, and stem cell therapy for ataxia specifically remains an area of ongoing study — see our general How Stem Cell Therapy Works page for the broader mechanism context.

Testimonials

Arjun K. – Mumbai, India – January 2020 – ⭐⭐⭐⭐☆
“My balance problems made daily life difficult. After Viezec’s stem cell therapy, my coordination improved, and I can walk more confidently now.”

Emma L. – London, UK – May 2020 – ⭐⭐⭐⭐⭐
“Ataxia left me unsteady and dependent on others. Post-treatment at Viezec, my tremors reduced and my independence increased.”

Hassan M. – Riyadh, Saudi Arabia – October 2020 – ⭐⭐⭐⭐☆
“Before therapy, my speech and balance were badly affected. Viezec’s care helped me regain steadiness and clearer communication.”

Maria R. – Madrid, Spain – March 2021 – ⭐⭐⭐⭐⭐
“Stem cell therapy gave me better motor control. My walking has improved, and I feel safer moving around without constant support.”

Peter J. – Berlin, Germany – September 2021 – ⭐⭐⭐⭐☆
“Ataxia symptoms slowed my life down. After treatment at Viezec, my coordination improved, and daily tasks are less challenging.”

Olivia S. – Toronto, Canada – February 2022 – ⭐⭐⭐⭐⭐
“My son’s balance issues were severe. After Viezec’s therapy, he now walks with more stability and has fewer falls.”

Ahmed A. – Cairo, Egypt – July 2022 – ⭐⭐⭐⭐☆
“I struggled with hand tremors due to ataxia. Stem cell therapy at Viezec reduced the shaking, and I can write again with control.”

Chloe D. – Sydney, Australia – April 2023 – ⭐⭐⭐⭐⭐
“Ataxia made my movements unpredictable. After therapy at Viezec, my balance improved, and I feel more confident outdoors.”

Marco V. – Rome, Italy – November 2023 – ⭐⭐⭐⭐☆
“I had difficulty speaking and moving steadily. Viezec’s stem cell therapy gave me gradual improvements in both speech and coordination.”

George P. – Athens, Greece – May 2025 – ⭐⭐⭐⭐⭐
“Before therapy, I was unsteady even at home. After Viezec’s treatment, I regained balance and confidence in walking without constant fear of falling.”

Treatment Disclaimer

Is stem cell therapy a guaranteed treatment for ataxia?

No. Stem cell therapy for ataxia is experimental and may not produce a response in every patient. A patient may be assessed as unsuitable, or a proposed protocol may be revised, depending on individual health status at the time of evaluation.

Does Viezec guarantee results?

No. As with any medical treatment, no cure or specific outcome is promised. Every patient’s internal biological status differs, so results vary even among patients with the same diagnosis. We do not offer, infer, or suggest certainty of any given outcome.

What cell sources are used?

We do not use embryonic or fetal cells in any treatment we provide.

Where can I get a specific answer for my case?

General information here cannot substitute for individual medical evaluation. Book a consultation to have your specific ataxia subtype and stage assessed directly.